Keto for Fatty Liver (MASLD): What the Evidence Supports

Short controlled feeding studies make a narrow but important point: reducing carbohydrate intake can reduce measured liver fat over days or weeks. That finding does not establish that a ketogenic diet treats metabolic dysfunction-associated steatohepatitis (MASH), reverses fibrosis, prevents cirrhosis, or is safe long term for people with metabolic dysfunction-associated steatotic liver disease (MASLD). The 2024 EASL-EASD-EASO guideline concludes that evidence is currently insufficient on the efficacy or safety of very-low-carbohydrate ketogenic diets in MASLD.¹

This page separates the short-term research signal from treatment claims. It uses the current MASLD terminology and explains why an internet diet guide cannot determine the cause or stage of liver disease.

Medical disclaimer. This article is for general educational purposes only and is not medical advice. It is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider before starting the ketogenic diet or making changes to your diet, exercise, or medication — especially if you are pregnant or breastfeeding, take medication, or have a medical condition such as diabetes, or kidney, liver, or heart disease. See our editorial & medical-review policy.

This page is educational and does not provide a carbohydrate target, ketogenic menu, medication plan, supplement or detox regimen, laboratory schedule, or a stop-or-continue rule. Diagnosis, disease staging, treatment selection, and any nutrition plan for liver disease belong with a clinician; a hepatologist and registered dietitian nutritionist may both be relevant depending on the situation.

MASLD, MASH, and the older NAFLD terms

In 2023, a multisociety Delphi process led by Mary Rinella and colleagues replaced the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with a steatotic-liver-disease framework.² Older studies, including several keto studies, still use NAFLD and NASH. The labels should not be swapped mechanically: MASLD uses positive cardiometabolic criteria and makes alcohol-related categories more explicit.

Term	Current meaning
Steatotic liver disease (SLD)	The umbrella term for excess fat in the liver from several possible causes.
MASLD	SLD with at least one of five cardiometabolic risk factors and no harmful alcohol intake.
MASH	Steatohepatitis in the MASLD setting. It includes inflammation and liver-cell injury, not just fat measured on imaging.
MetALD	A distinct category for metabolic dysfunction with a higher alcohol exposure range.

This distinction matters because an imaging result that shows liver fat does not, by itself, establish the cause or the stage. Clinicians consider the full context, including cardiometabolic risk, alcohol exposure, medicines, and other possible liver conditions. A page about keto cannot make that classification.¹²

What carbohydrate-restriction studies actually found

The studies most often cited in support of keto and fatty liver were short metabolic experiments. They are useful for understanding liver-fat biology, but their duration, size, and endpoints set clear limits on the conclusion.

Study	Relevant finding	What it cannot show
Mardinoglu et al., 2018	In 10 people with obesity and high liver fat, 14 days of an isocaloric carbohydrate-restricted, higher-protein diet reduced liver fat measured by magnetic-resonance spectroscopy by a mean 43.8%.3	Whether the intervention resolves MASH, regresses fibrosis, improves clinical outcomes, or remains safe and workable over months or years.
London et al., 2024	In a four-day randomized crossover study of men with overweight or obesity, an energy-matched low-carbohydrate, high-fat period reduced liver triacylglycerol content and changed hepatic metabolic measures.4	Whether the result applies to people with diagnosed MASLD, different causes or stages of liver disease, or a long-term ketogenic diet.
Vilar-Gomez et al., 2015	In 293 people with biopsy-confirmed NASH followed through a lifestyle intervention, greater weight loss was associated with better histologic outcomes at 52 weeks.5	A keto-specific effect. The study did not isolate a ketogenic diet.

The first two studies support a mechanism: carbohydrate restriction can change liver triacylglycerol and related metabolism quickly, even when energy intake is controlled. They are not proof that nutritional ketosis is a disease-specific therapy. Their short timelines also make them poorly suited to answer questions about fibrosis, cirrhosis, cardiovascular risk, kidney effects, or long-term adherence.

Why a quick reduction in liver fat is not the same as disease reversal

Magnetic-resonance measures of liver fat are meaningful research outcomes, but they are not interchangeable with liver histology or liver-related clinical outcomes. MASH involves inflammation and liver-cell injury; fibrosis concerns scar tissue. Each may move on a different timeline from a change in liver fat. The 52-week Vilar-Gomez study is relevant because it used paired biopsies, but it was a lifestyle study rather than evidence that keto itself produces those outcomes.⁵

EASL-EASD-EASO guidance describes population-level targets for adults with MASLD and overweight: sustained weight loss of at least 5% is associated with lower liver fat, 7% to 10% with improved liver inflammation, and at least 10% with improved fibrosis.¹ These are guideline-level evidence statements, not a promise or a self-directed target for any one person. The same guideline says hypocaloric low-carbohydrate and low-fat patterns appear similarly effective for liver lipid content and related biomarkers, while Mediterranean-style dietary quality may add cardiometabolic value and be easier to sustain.¹

Why current guidelines remain cautious about keto

The key limitation is not that the short-term studies found nothing. They found changes in liver fat. The limitation is that those studies do not answer the questions needed to endorse a very restrictive ketogenic diet as a MASLD treatment: durable disease outcomes, safety across comorbidities, and performance in people with more advanced disease.

The 2024 EASL-EASD-EASO guideline specifically states that evidence is insufficient on the efficacy or safety of very-low-carbohydrate ketogenic diets in MASLD, noting possible cardiovascular, kidney, and other effects.¹ The earlier AASLD practice guidance also described low-carbohydrate, low-fat, intermittent-fasting, and Mediterranean-style approaches as broadly comparable for improving NAFLD/NASH, while emphasizing dietary quality and cardiovascular considerations.⁶

That caution is especially relevant when liver disease may be advanced or when diabetes, kidney disease, cardiovascular disease, pregnancy, a history of disordered eating, or prescribed medicines affect nutrition choices. Those factors do not automatically decide the answer, but they make a generic keto protocol unsafe.

What a clinician-first decision needs to establish

Before a dietary pattern is treated as part of liver care, the clinical questions are more basic than a keto food list:

1. What cause and stage of steatotic liver disease has actually been established?
2. Is there evidence of MASH, fibrosis, cirrhosis, or another liver condition that changes care?
3. Which cardiometabolic conditions and prescribed medicines affect dietary risk or follow-up?
4. Which outcome is the care team trying to improve, and how will it be assessed?

Those questions explain why this article does not offer a liver-disease version of a macro calculator, a fasting schedule, a supplement stack, or a detox. General background on the science of ketosis and the safety-first keto decision guide can explain the diet's broader context, but neither replaces liver-disease assessment.

Frequently Asked Questions

Frequently Asked Questions

Is NAFLD now called MASLD?

MASLD is the current term for a large part of what older research called NAFLD, but it is not a word-for-word replacement. The newer definition requires hepatic steatosis plus cardiometabolic risk criteria and distinguishes alcohol-related categories more explicitly.

Does keto cure or reverse fatty liver?

No current evidence supports that guarantee. Short controlled studies show carbohydrate restriction can reduce measured liver fat, but they do not establish MASH resolution, fibrosis regression, cirrhosis prevention, or long-term safety of ketogenic diets in MASLD.

Why do people cite rapid liver-fat reductions?

They come from short metabolic studies with imaging or spectroscopy outcomes. Those studies are valuable for studying liver-fat metabolism, but they are not long-term treatment trials with biopsy-confirmed or clinical endpoints.

Why are liver guidelines cautious about ketogenic diets?

The current EASL-EASD-EASO guideline finds insufficient evidence on the efficacy or safety of very-low-carbohydrate ketogenic diets in MASLD. It cites the need to consider cardiovascular, kidney, and other effects alongside uncertain long-term liver outcomes.

Can this page tell me whether keto is safe for my fatty liver?

No. Safety depends on the cause and stage of liver disease, other conditions, and prescribed medicines. That is a clinician-led decision, not one that can be made from a general article.

The bottom line

Carbohydrate restriction can reduce measured liver fat in short, controlled studies. That is a real research finding, not a substitute for evidence on MASH, fibrosis, cirrhosis, or long-term safety. Current EASL-EASD-EASO guidance does not establish very-low-carbohydrate ketogenic diets as a MASLD treatment because those longer-term efficacy and safety questions remain unresolved.¹ For anyone with known or suspected liver disease, clinical classification and staging come before a diet protocol.

Works cited

1. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) — European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity, *Journal of Hepatology*, 2024 — August 25, 2026 https://doi.org/10.1016/j.jhep.2024.04.031
2. A multisociety Delphi consensus statement on new fatty liver disease nomenclature — Rinella et al., *Hepatology*, 2023 — August 25, 2026 https://doi.org/10.1097/HEP.0000000000000520
3. An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans — Mardinoglu et al., *Cell Metabolism*, 2018 — August 25, 2026 https://pubmed.ncbi.nlm.nih.gov/29456073/
4. The impact of short-term eucaloric low- and high-carbohydrate diets on liver triacylglycerol content in males with overweight and obesity: a randomized crossover study — London et al., *The American Journal of Clinical Nutrition*, 2024 — August 25, 2026 https://pubmed.ncbi.nlm.nih.gov/38914224/
5. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis — Vilar-Gomez et al., *Gastroenterology*, 2015 — August 25, 2026 https://pubmed.ncbi.nlm.nih.gov/25865049/

Article history

1. August 25, 2026Rewritten for current MASLD terminology and safer evidence boundaries; removed diet protocol, self-monitoring, and treatment claims.
2. August 19, 2026First published